Estimations des analystes de Wall Street pour Arcturus Therapeutics Holdings Inc. (ARCT): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.67 | ||
| 2026-08-06 | $-0.84 | $-1.00 | +15.7% |
| 2026-05-07 | $-0.95 | $-1.03 | +7.4% |
| 2026-03-03 | $-1.03 | $-0.92 | -12.0% |
| 2025-11-10 | $-0.49 | $-0.80 | +38.7% |
| 2025-08-11 | $-0.34 | $-0.89 | +61.9% |
| 2025-05-12 | $-0.52 | $-1.58 | +67.1% |
| 2025-03-06 | $-1.11 | $-0.33 | -236.4% |
Ratios de valorisation
| Prix / Valeur comptable | 2.44 |
| EV / EBITDA | -3.33 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $20.4M | $13.0M | $15.8M | $20.8M | $9.5M | $12.4M | $205.8M | $157.7M | $138.4M | $67.2M |
| Coût des Ventes | $294000 | $410000 | $17.0M | 0 | $55.9M | 0 | 0 | 0 | 0 | $3.0M |
| Marge Brute | $20.1M | $12.6M | -$1.2M | $20.8M | -$46.4M | $12.4M | $205.8M | $157.7M | $138.4M | $64.2M |
| R&D | $18.4M | $15.9M | $17.0M | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | $112.2M |
| Frais Généraux | $5.4M | $7.6M | $20.6M | $12.7M | $25.1M | $41.5M | $46.1M | $52.9M | $52.8M | $46.1M |
| Charges Opérationnelles | $25.2M | $23.5M | $37.6M | $46.3M | $25.1M | $215.2M | $193.6M | $236.0M | $234.1M | $139.2M |
| Résultat Opérationnel | -$25.2M | -$10.5M | -$21.8M | -$25.5M | -$71.5M | -$202.9M | $12.2M | -$78.2M | -$95.7M | -$75.0M |
| EBITDA | -$947000 | -$10.3M | -$20.7M | -$24.5M | -$70.6M | -$199.8M | $15.2M | -$24.2M | -$77.4M | -$62.8M |
| Charges d'Intérêt | $295000 | $150000 | $186000 | $854000 | $831000 | $2.7M | $3.0M | $767000 | 0 | 0 |
| Résultat Avant Impôts | -$24.5M | -$10.9M | -$21.8M | -$26.0M | -$72.1M | -$203.7M | $10.6M | -$27.9M | -$80.9M | -$65.8M |
| Impôts | $73000 | $1000 | $212000 | 0 | 0 | 0 | $1.3M | $1.8M | -$4000 | 0 |
| Résultat Net | -$24.6M | -$10.9M | -$21.8M | -$26.0M | -$72.1M | -$203.7M | $9.3M | -$29.7M | -$80.9M | -$65.8M |
| BPA | $-6.25 | $-3.53 | $-2.16 | $-2.13 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3.00 | $-2.40 |
| BPA Dilué | $-6.25 | $-3.53 | $-2.16 | $-2.13 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3.00 | $-2.40 |
| Actions en Circulation (Diluées) | $3.9M | $3.1M | $10.1M | $12.1M | $20.3M | $26.3M | $27.1M | $26.6M | $27.0M | $27.4M |
Prix
| Prix | $15.60 |
| Capitalisation | $443M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ACHV · AVIR · FHTX · HUMA · IMRX · SGMT · TRDA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ARCT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions